Repeated Polysomnograms Aft er Antiinfl ammatory Th erapy of Mild Pediatric OSA
To the Editor:
We read the recent article in CHEST (July 2014) by Kheirandish-Gozal et al 1 with great interest. Over the past 2 decades, there have been several publications on the use of antiinfl ammatory medications for the treatment of mild OSA in children. Taken together, they provide increasingly compelling evidence that, at least for a select subset of patients, our medical fi eld may need to undergo a paradigm shift from a surgical to a medical approach for the treatment of this relatively common condition.
Th e authors made a signifi cant contribution to the available literature, as their article is the most robust to date in terms of both the breadth (ie, large number of subjects) and the depth (ie, performing serial polysomnograms). We agree with the authors' conclusion that a multicenter randomized trial is needed to further corroborate these results, but, in the meantime, we are hoping that the authors would be able to shed some light on a specifi c aspect of this treatment approach that has not been adequately addressed in the literature. Several authorities in this medical fi eld, such as Marcus, 2 proposed that it may be necessary to routinely perform polysomnography on patients treated with antiinfl ammatory medications due to the inherent limitations of the clinical evaluation in correctly identifying patients with OSA. We respectfully ask the current authors if they could address this question given the data they collected for this article, namely, what was the reliability of the posttreatment symptoms in discriminating between persistence or resolution of OSA on the posttreatment polysomnograms? 
Response
To the Editor:
We greatly appreciate the favorable comments of Drs Traeger and Prashad regarding our clinical experience using antiinfl ammatory therapy in children with mild OSA as an alternative to surgical adenotonsillectomy (T&A). 1 Th ey raise a major and pertinent clinical question as to whether persistence or changes in clinical symptoms associated with treatment can guide the need for a follow-up polysomnographic evaluation aft er completion of treatment or guide the need for continued antiinfl ammatory treatment or alternative treatments. Because of the retrospective nature of our study, we are clearly unable to formulate a scientifi cally valid answer to this query. However, some of our previous studies focused on T&A for pediatric OSA would suggest that the presence or absence of clinical symptoms aft er treatment are markedly unreliable in the identifi cation of residual OSA, while also suggesting specifi c high-risk groups that are more likely to exhibit residual OSA aft er T&A (eg, presence of obesity, older age, severe OSA pre-T&A). 2 -4 Furthermore, we would strongly endorse implementation of coordinated multicenter eff orts aimed at delineating instruments that incorporate both symptoms and physical fi ndings in the pursuit of not only the diagnosis of OSA but also the presence of residual OSA aft er treatment. 5 David 
